Systemic reactogenicity following homologues and heterologous prime-boost AZD1222 and BNT162b2 COVID-19 vaccination of 2862 healthcare workers compared with an unvaccinated population

During spring 2021, AZD1222 and BNT162b2 were used as prime and BNT162b2 as booster COVID-19 vaccines in Denmark. We obtained self-reported information on systemic reactogenicity day-by-day during two weeks for 2862 healthcare workers vaccinated with heterologous AZD1222 + BNT162b2 or homologous BNT...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabatabaeifar, Sorosh, Vestergaard, Jesper M., Würtz, Else T., Hansen, Karoline K., Nielsen, Kent J., Schlünssen, Vivi, Kolstad, Henrik A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Short communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010832/
https://www.ncbi.nlm.nih.gov/pubmed/36945661
http://dx.doi.org/10.1016/j.jvacx.2023.100280
Descripción
Sumario:During spring 2021, AZD1222 and BNT162b2 were used as prime and BNT162b2 as booster COVID-19 vaccines in Denmark. We obtained self-reported information on systemic reactogenicity day-by-day during two weeks for 2862 healthcare workers vaccinated with heterologous AZD1222 + BNT162b2 or homologous BNT162b2 + BNT162b2 regimens and compared prevalences of symptoms with unvaccinated healthcare workers. We found comparable systemic reactogenicity during the first week in the two vaccine regimens and no reactogenicity during the second week. Most of the symptoms returned to a level equal to the control population four days after booster vaccination.

Ejemplares similares